Tag: Ocugen

The U.S. Food and Drug Administration has removed the clinical hold on Ocugen's promising ocular therapeutic candidate OCU200, clearing the ...

The biotechnology sector is watching Ocugen with keen interest as the company makes waves with its bold strategic vision. At ...

A prolonged regulatory standoff with U.S. health authorities has concluded favorably for Ocugen. The biopharmaceutical company announced that the Food ...

After an extended period of lateral trading, shares of biotechnology firm Ocugen are attracting renewed market interest. The catalyst appears ...

Pennsylvania-based biotech firm Ocugen captured significant market attention on Friday as its stock reached a new 52-week peak. This substantial ...

Ocugen has captured market attention with a bold regulatory roadmap, announcing plans to submit three gene therapy applications to the ...

The biotech sector has a standout performer as Ocugen's stock demonstrates remarkable momentum, reaching fresh milestones while many peers struggle. ...

The biotechnology firm Ocugen has captured market attention with a remarkable performance surge, gaining more than 26% over a two-week ...

Ocugen is executing a strategic campaign to position itself at the forefront of gene therapy. The company has announced a ...

A surge in bullish options trading has drawn significant attention to biotech firm Ocugen, with market participants taking substantial positions ...